Fig. 3.

Adjusted mean change from baseline in “General Acceptance” score of the ACCEPT questionnaire by visit for participants without prior CAB + RPV exposure (a) and with prior CAB + RPV exposure (b)^a. ACCEPT Chronic Treatment Acceptance Questionnaire, ANCOVA analysis of covariance, CAB cabotegravir, CI confidence interval, LA long-acting, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine. ^aNo prior exposure, Week 24: Q8W, n = 319; Q4W, n = 323; Week 48: Q8W, n = 319; Q4W, n = 324; prior exposure, Week 24: Q8W, n = 192; Q4W, n = 194; Week 48: Q8W, n = 192; Q4W, n = 194. Adjusted mean change from baseline calculated from an ANCOVA model including the following covariates: baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), and race (white, non-white) for participants with no prior exposure; baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), race (white, non-white), and prior exposure to CAB + RPV (1–24, > 24 weeks) for participants with prior exposure